| Drug Name |
Terconazole |
| Drug ID |
BADD_D02164 |
| Description |
Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a _triazole ketal derivative_.[A178096] Terconazole was initially approved by the FDA in 1987.[FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials. [A178093] |
| Indications and Usage |
For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina. |
| Marketing Status |
approved |
| ATC Code |
G01AG02 |
| DrugBank ID |
DB00251
|
| KEGG ID |
D00888
|
| MeSH ID |
C037815
|
| PubChem ID |
441383
|
| TTD Drug ID |
D01AQT
|
| NDC Product Code |
0168-0347; 45802-717; 53002-7240; 50090-6299; 53002-8130; 0713-0552; 22568-1125; 0168-0346; 51672-1330; 63629-8837; 50090-1196; 51672-1302; 50090-0917; 59349-0011; 50090-6266; 51672-1304 |
| UNII |
0KJ2VE664U
|
| Synonyms |
terconazole | 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine | Fungistat | R 42470 | Terazol | Gyno-Terazol |
